ArticlePloS one2026
Theory-based predictors of prescribing behaviour for neurodegenerative diseases: A cross-sectional survey with European healthcare professionals.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesExplore the likelihood of healthcare professionals (HCPs) prescribing a new, novel or different to usual medication to patients with a newly diagnosed early onset or advanced stage neurodegenerative disease (ND), and identification of the theoretical behavioural determinants that underpin these predictors.
designA quantitative cross-sectional study using a newly developed survey underpinned by the Theoretical Domains Framework (TDF) was delivered online between September 2023 and March 2024.
settingAll levels of healthcare where medication is prescribed for NDs across Austria, France, Germany, Italy, the Netherlands, Spain, Sweden and the UK.
participantsRecruited predominately via a participation panel, HCPs who have prescribed medication for a ND in the past 2 years were eligible to take part, with 279 participants (66% male) completing the study in full. PRIMARY AND SECONDARY OUTCOME MEASURES: The primary outcome was HCPs' likelihood of prescribing a new, novel or different to usual medication compared with their routine choice for patients with a newly diagnosed early onset or advanced stage ND. A secondary outcome was to identify factors aligned to the TDF that influenced prescribing and describe them using the Capability, Opportunity and Motivation - Behaviour (COM-B) model.
resultsHCPs were significantly more likely to consider prescribing outside of routine habit for patients with advanced stage ND compared to patients with new early onset diagnosis (60.8% [95% confidence interval (CI) 57.70, 63.95] vs 51.8% [95% CI 48.61, 55.05], respectively). Logistic regression models revealed a total of four factors that predicted prescribing. In the scenario with newly diagnosed patients, HCP intention (β = 0.324, 95% CI 4.75, 10.69), behavioural regulation (β = 0.191, 95% CI 1.57, 8.92), and social/professional role and identity (β = ‑0.184, 95% CI 1.57, 8.92) were each significant predictors of prescribing. In the scenario with patients with advanced stage ND, HCP intention also predicted prescribing (β = 0.234, 95% CI 31.02, 65.15), along with HCP belief about consequences (β = -0.145, 95% CI 2.73, 8.11). Thus, the TDF determinants that predicted prescribing indicate that COM-B capability (TDF behavioural regulation) and motivation (TDF intention, social/professional role and identity, and belief about consequences) domains may be relevant targets for changing prescribing habits.
conclusionsThere is a complex interplay of specific and generic predictors that influence prescribing for patients with a newly diagnosed early onset or advanced stage ND. Appropriate behaviour change frameworks that target HCPs' capability and motivation should be considered to support changes towards the optimal use of new, novel or different to usual medication in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.